58 patents
Page 2 of 3
Utility
Antigen-Binding Polypeptide Constructs Comprising Kappa and Lambda Light Chains and Uses Thereof
18 Nov 21
Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain.
Dunja UROSEV, Stacey A.L. TOM-YEW, Leonard G. PRESTA, Mario SANCHES
Filed: 27 Apr 21
Utility
ANTI-HER2 Biparatopic Antibody-drug Conjugates and Methods of Use
11 Nov 21
Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer.
Kevin Hamblett, Rupert H. Davies, James R. Rich, Gerald J. Rowse, Vincent K.C. Fung, Stuart D. Barnscher
Filed: 23 Mar 21
Utility
Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
2 Nov 21
Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain.
Dunja Urosev, Stacey A. L. Tom-Yew, Leonard G. Presta, Mario Sanches
Filed: 7 Oct 16
Utility
Drug-conjugated bi-specific antigen-binding constructs
19 Oct 21
Bispecific antigen-binding constructs e.g., antibodies conjugated to drugs (ADCs), which bind CD3 and other cell-surface target antigen such as tumor antigens e.g., CD19, CDH3, HER2, HER3 and EGFR antigens and methods of use are disclosed.
Gordon Yiu Kon Ng, Leonard G. Presta, Thomas Spreter Von Kreudenstein
Filed: 15 Jul 16
Utility
Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
19 Oct 21
The invention provides methods and systems of determining biopolymer profiles and correlations between structural units (residues) of a biopolymer based on sampling of the conformational space available to the molecule.
Paula I. Lario, Johannes Mullegger, Surjit B. Dixit, Tomas Rodinger, Powell Patrick Cheng Tan
Filed: 27 Jul 16
Utility
Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
14 Oct 21
Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells.
Gordon Yiu Kon Ng, Surjit Bhimarao Dixit, Thomas Spreter von Kreudenstein, Nina E. Weisser
Filed: 19 Mar 21
Utility
Engineered Immunoglobulin Heavy Chain-Light Chain Pairs and Uses Thereof
7 Oct 21
Provided are heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain.
Adam Louis Corper, Dunja Urosev, Stacey A.L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
Filed: 9 Jun 21
Utility
STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAIN
9 Sep 21
The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g.
Thomas Spreter Von Kreudenstein, Eric Escobar-Cabrera, Surjit Bhimarao Dixit, Paula Irene Lario, David Kai Yuen Poon, Igor D'Angelo
Filed: 30 Nov 20
Utility
Methods Using Monovalent Antigen Binding Constructs Targeting HER2
2 Sep 21
Provided herein are methods of use and treatment using a first or a first and second monovalent antigen-binding constructs targeting HER2.
Gordon Yiu Kon NG, Nina E. WEISSER, Grant Raymond WICKMAN
Filed: 17 Dec 20
Utility
ANTI-HER2 Biparatopic Antibody-drug Conjugates and Methods of Use
26 Aug 21
Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer.
Kevin HAMBLETT, Rupert H. DAVIES, James R. RICH, Gerald J. ROWSE, Vincent K.C. FUNG, Stuart D. BARNSCHER
Filed: 12 Mar 19
Utility
Heteromultimers with reduced or silenced effector function
24 Aug 21
Provided herein are heteromultimer constructs with reduced or silenced effector function.
Eric Escobar-Cabrera
Filed: 30 May 14
Utility
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
3 Aug 21
Provided are heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain.
Adam Louis Corper, Dunja Urosev, Stacey A. L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
Filed: 14 Feb 18
Utility
Anti-PD-1/LAG3 bispecific antibodies
27 Jul 21
Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments.
Laurence Fayadat-Dilman, Veronica Juan, Shireen Khan, Shaopeng Huang, Hua Ying, Eric Escobar Cabrera, Genevieve Desjardins
Filed: 31 Jan 19
Utility
Methods of Using Bispecific Antigen-binding Constructs Targeting HER2
24 Jun 21
Described herein methods of using antigen-binding constructs to treat HER2+ tumors in a subject such as breast, lung, or head and neck tumors.
Grant Raymond Wickman, Gordon Yiu Kon Ng, Nina E. Weisser
Filed: 25 Sep 20
Utility
Methods of Using a Bispecific Antigen-binding Construct Targeting HER2 In Combination with CDK4/6 Inhibitors for the Treatment of Breast Cancer
10 Jun 21
Described herein is a method of treating breast cancer comprising administering a bispecific antigen-binding construct targeting HER2 or a bispecific antigen-binding construct targeting HER2 linked to an auristatin analogue (ADC) in combination with a CDK4/6 inhibitor to a subject.
Nina E. Weisser, Diana F. Hausman, Patrick Kaminker
Filed: 29 May 20
Utility
Antigen-binding constructs targeting HER2
8 Jun 21
Described herein are high affinity antigen binding constructs, e.g., antibodies, directed to the ECD2 domain of HER2.
Eric Escobar-Cabrera, Leonard G. Presta
Filed: 13 May 16
Utility
Systems and methods for identifying thermodynamically relevant polymer conformations
8 Jun 21
Systems, methods and non-transitory computer readable media identify favored polymer conformations.
Gregory Lakatos, Surjit Bhimarao Dixit
Filed: 21 Jun 13
Utility
Anti-HER2 biparatopic antibody-drug conjugates and methods of use
11 May 21
Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer.
Kevin Hamblett, Rupert H. Davies, James R. Rich, Gerald J. Rowse, Vincent K. C. Fung, Stuart D. Barnscher
Filed: 7 Oct 19
Utility
Bispecific antigen-binding constructs targeting HER2
16 Mar 21
Provided herein are biparatopic antigen-binding constructs that specifically bind HER2.
Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
Filed: 27 Nov 14
Utility
Multivalent Heteromultimer Scaffold Design and Constructs
14 Jan 21
Provided herein are multifunctional heteromer proteins.
Surjit Bhimarao Dixit, Igor Edmondo Paolo D'Angelo, David Kai Yuen Poon
Filed: 10 Jun 20